Irish cell-based manufacturing firm Valitacell has teamed up with the UK’s Solentim on a project aimed at enabling earlier identification of biological candidates.
Solentim, a Bournemouth-based firm which produces cell line development instruments, will work with Valitacell to try to accelerate the development of breakthrough medicines.
The collaboration will leverage Valitacell’s in-line analytical profiling technologies and data driven/machine learning approach, together with Solentim’s image-driven liquid handling and cell measurement technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze